Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc., an established leader in antisense drug development.

The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne Muscular Dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

Antisense Therapeutics’ strategy is:

• To create antisense drugs for diseases where there are large and/or poorly met markets, in collaboration with Antisense Therapeutics’ technology and research partners
• To advance these drugs successfully through pre-clinical and clnical development via out-sourcing arrangements with expert contractors
• To commercialise the drugs that are shown to be successful in clinical testing by entering into licensing deals or other partnerships with major pharmaceutical companies.